768P Survival and benefit of adjuvant chemotherapy (ACT) by circulating tumor DNA (ctDNA)-based pretreatment genomic profile and postoperative molecular residual disease (MRD) in resectable colorectal oligometastases (CRM): PRECISION, a prospective multicenter study
S. Kobayashi(National Cancer Center Hospital East), Yoshitsugu Nakamura(Osaka University of Pharmaceutical Sciences), S. Yasuta(Sendai Kousei Hospital), Yoshiaki Takahashi(Kyushu University), Soichiro Natsume(Tokyo Metropolitan Komagome Hospital), Akiko Takahashi(Japanese Foundation For Cancer Research), Hiroaki Taniguchi(Kanazawa University), Daisuke Nobuoka(Fukuyama City Hospital), M. Shiozawa(Kanagawa Prefectural Hospital Organization), Akio Shiomi(Shizuoka Cancer Center), Takuma Kojima(Okayama Saiseikai General Hospital), Eiji Oki(Kyushu University), Taigo Kato(Osaka City University), Akinobu Taketomi(Hokkaido University), Y. Nishizawa(Osaka Prefectural Medical Center), Masatoshi Wakabayashi(National Cancer Center Hospital East), Yasuyuki Takamizawa
Cited by 1
Related Papers
Exosomes maintain cellular homeostasis by excreting harmful DNA from cells
|Nature Communications|2017|748
A DNA methylation fingerprint of 1628 human samples
|Genome Research|2011|418
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366